Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersanaâs lead product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC and other cancers. In addition, multiple partners are using Mersanaâs platform to advance their ADC pipelines. Source
No articles found.
Curis is a biotechnology company focused on the development and commercialization ...
Curis is a biotechnology company focused on the...
Restance is pursuing several business lines in the growing economies of East Afric...
Restance is pursuing several business lines in ...
Commitment to quality, community and people are basic tenets for Quorum Health. As...
Commitment to quality, community and people are...
BridgeBio finds, develops, and delivers breakthrough medicines for genetic disease...
BridgeBio finds, develops, and delivers breakth...
Join the National Investor Network and get the latest information with your interests in mind.